What are the recommended dosing regimens for horse anti‑thymocyte globulin, cyclosporine, eltrombopag, and the reduced‑intensity conditioning protocol (fludarabine and cyclophosphamide) for allogeneic hematopoietic stem‑cell transplantation in a patient with aplastic anemia?

Recommended Dosing Regimens for Allogeneic HSCT in Aplastic Anemia

For aplastic anemia patients undergoing allogeneic HSCT, use fludarabine 120 mg/m² (total dose over days -5 to -2), cyclophosphamide 90-200 mg/kg (total dose), and horse ATG 10 mg/kg (total dose over days -5 to -2) or ATG-F 20-40 mg/kg (total dose over days -5 to -2), with cyclosporine 10-12 mg/kg/day adjusted to blood levels. 1

Conditioning Regimen Selection by Donor Type

HLA-Matched Sibling Transplantation

The Cy-ATG regimen is the standard approach 1:

• Cyclophosphamide: 200 mg/kg total dose, administered on days -5 through -2
• ATG (Thymoglobuline): 11.25-15.00 mg/kg total dose, given on days -5 through -3 or -2

HLA-Matched Unrelated Donor Transplantation

The FluCy-ATG regimen is preferred 1:

• Fludarabine: 120 mg/m² total dose, administered on days -5 through -2
• Cyclophosphamide: 120 mg/kg total dose, given on days -5 and -2
• ATG (Thymoglobuline): 11.25-15.00 mg/kg total dose, administered on days -5 through -3 or -2

Haploidentical Transplantation

Two primary regimens are used in China 1:

Option 1: mBuCyFluATG

• Busulfan: 6.4 mg/kg IV total dose, days -7 through -6
• Fludarabine: 120 mg/m² total dose, days -10 through -7
• Cyclophosphamide: 200 mg/kg total dose, days -6 through -3
• ATG-F: 20 mg/kg total dose, days -4 through -1
• OR ATG (Thymoglobuline): 10 mg/kg total dose, days -4 through -1

Option 2: FluCy-ATG (Reduced Intensity)

• Fludarabine: 120 mg/m² total dose, days -5 through -2
• Cyclophosphamide: 90 mg/kg total dose, days -3 and -2
• ATG (Thymoglobuline): 10 mg/kg total dose, days -5 through -2

ATG Product-Specific Dosing

The choice between ATG products affects total dose 1:

• ATG (Thymoglobuline, Sanofi-Genzyme): 10 mg/kg total dose for alternative donor transplants
• ATG-F (Grafalon, Fresenius): 40 mg/kg total dose for matched sibling/unrelated donors; 20 mg/kg for haploidentical transplants

Cyclosporine Dosing for GVHD Prophylaxis

Initial dosing: 10-12 mg/kg/day, divided into two doses, adjusted to maintain therapeutic blood trough levels 2. Treatment duration is typically 6 months for immunosuppressive therapy alone 2. When used post-transplant, cyclosporine should be combined with methotrexate or mycophenolate mofetil for GVHD prophylaxis 3, 4.

Monitoring requirements 5:

• Measure blood trough concentrations at least twice weekly initially
• Daily monitoring if initial dose exceeds 10 mg/kg/day
• Continue frequent monitoring until levels stabilize within target range
• Adjust dose by 25-50% for adverse events including hypertension or creatinine elevation ≥30% above baseline

Eltrombopag Integration

While the provided evidence does not contain specific dosing protocols for eltrombopag in the transplant setting, recent guidelines indicate it can be added to immunosuppressive regimens 6. Standard dosing for aplastic anemia treatment typically starts at 50 mg daily (25 mg for East Asian patients), but transplant-specific protocols require consultation with current institutional guidelines.

Age-Based Considerations

Younger patients (<15 years): Standard fludarabine-based reduced-intensity regimens show excellent outcomes with lower rejection rates (5%) and 84% actuarial survival 4.

Older patients (≥15 years): May require modification of conditioning intensity. Patients >15 years receiving fludarabine/cyclophosphamide/ATG had higher graft failure risk (18% overall) 4. Consider adding low-dose TBI (2 Gy) for patients >15 years 3.

Patients >40 years: Fludarabine 30 mg/m²/day for 6 days plus cyclophosphamide 60 mg/kg/day for 2 days (without ATG) showed 75.3% 5-year survival in matched related donor transplants 7.

Critical Dosing Nuances

Fludarabine administration: The 120 mg/m² total dose is typically divided over 4 days (30 mg/m²/day × 4 days) 3, 4. Some protocols use 6-day administration at 30 mg/m²/day for a total of 180 mg/m² 7.

Cyclophosphamide cardiotoxicity: The shift from traditional high-dose cyclophosphamide (200 mg/kg) to reduced doses (90-120 mg/kg) when combined with fludarabine reduces cardiotoxicity while maintaining efficacy 8.

ATG timing: Administration typically begins 5 days before stem cell infusion (day -5) and continues through day -2 or -1, allowing adequate T-cell depletion while minimizing delayed engraftment 1.

Common Pitfalls to Avoid

• Do not use grapefruit juice as a diluent for cyclosporine oral solution, as it affects drug metabolism 5
• Avoid live vaccines during and after fludarabine-based conditioning 9
• Monitor for graft failure more closely in patients ≥15 years receiving reduced-intensity conditioning without TBI 4
• Distinguish between ATG products: Thymoglobuline and ATG-F (Fresenius) require different total doses (10 mg/kg vs 20-40 mg/kg respectively) 1

The evidence strongly supports fludarabine-based reduced-intensity conditioning as the modern standard, replacing older cyclophosphamide-only regimens to reduce toxicity while maintaining efficacy 3, 4, 7, 8.